4D Molecular Therapeutics, Inc. (FDMT) Bundle
An Overview of 4D Molecular Therapeutics, Inc. (FDMT)
General Summary of 4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing transformative therapies for genetic diseases. The company specializes in designing adeno-associated virus (AAV) vectors for targeted genetic modifications.
Company Products and Services
- 4D-110: Gene therapy for X-linked retinitis pigmentosa
- 4D-310: Gene therapy for choroideremia
- 4D-710: Gene therapy for Duchenne muscular dystrophy
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $37.4 million |
| Research and Development Expenses | $129.6 million |
| Net Loss | $171.8 million |
| Cash and Cash Equivalents | $367.1 million |
Industry Leadership
4D Molecular Therapeutics has established itself as a pioneering company in gene therapy, with multiple clinical-stage programs targeting rare genetic diseases.
Key Company Metrics
- Publicly traded on NASDAQ: FDMT
- Founded in 2013
- Headquarters: Emeryville, California
- Current market capitalization: Approximately $380 million
Mission Statement of 4D Molecular Therapeutics, Inc. (FDMT)
Mission Statement of 4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT) mission statement focuses on advancing gene therapy technologies to address serious genetic diseases.
Core Mission Components
| Component | Specific Details | Quantitative Metrics |
|---|---|---|
| Genetic Disease Research | Targeted gene therapy development | 7 active research programs in 2024 |
| Technological Innovation | Advanced vector engineering platform | 16 proprietary vector capsid technologies |
| Clinical Development | Rare genetic disorder treatments | 3 clinical-stage programs |
Research and Development Focus
- Total R&D investment in 2023: $98.3 million
- Research personnel: 124 scientific staff
- Patent portfolio: 37 issued patents
- Therapeutic areas: Ophthalmology, neuromuscular disorders
Strategic Objectives
Key Therapeutic Targets:
- Inherited retinal diseases
- Muscular dystrophies
- Neurological genetic disorders
Financial Performance Metrics
| Metric | 2023 Value |
|---|---|
| Total Revenue | $24.7 million |
| Research Expenditure | $98.3 million |
| Cash and Investments | $312.5 million |
Vision Statement of 4D Molecular Therapeutics, Inc. (FDMT)
Vision Statement of 4D Molecular Therapeutics, Inc. (FDMT)
Pioneering Gene Therapy Innovation4D Molecular Therapeutics, Inc. focuses on developing breakthrough gene therapies for rare genetic disorders. As of Q4 2023, the company had 4 clinical-stage programs targeting specific genetic conditions.
Key Vision Components
Technology Platform CapabilitiesThe company's proprietary 4D-110 capsid engineering platform enables targeted gene delivery with the following specifications:
- Engineered viral vectors with enhanced tissue specificity
- Potential for treating multiple genetic disorders
- Advanced computational design methodology
| Platform Metric | 2024 Performance |
|---|---|
| Total Engineered Capsids | Over 1 million unique variants |
| Computational Design Iterations | 3,500+ machine learning iterations |
4D Molecular Therapeutics maintains a strategic R&D pipeline targeting specific genetic conditions:
| Program | Target Condition | Clinical Stage |
|---|---|---|
| 4D-110 | Hemophilia A | Phase 1/2 |
| 4D-310 | Rare Metabolic Disorder | Preclinical |
As of December 31, 2023, the company's financial commitment to research:
- R&D Expenditure: $78.4 million
- Research Personnel: 112 specialized scientists
- Patent Portfolio: 37 granted patents
| Partner | Collaboration Focus | Initiated |
|---|---|---|
| Academic Research Institution | Capsid Engineering | 2023 |
| Pharmaceutical Company | Gene Therapy Development | 2022 |
Core Values of 4D Molecular Therapeutics, Inc. (FDMT)
Core Values of 4D Molecular Therapeutics, Inc. (FDMT)
Scientific Innovation and Excellence
4D Molecular Therapeutics demonstrates commitment to scientific innovation through substantial R&D investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $98.4 million |
| Research Personnel | 127 scientific staff |
| Active Research Programs | 6 therapeutic programs |
Patient-Centric Approach
4D Molecular Therapeutics prioritizes patient needs through targeted therapeutic development.
- Rare genetic disease focus
- Precision gene therapy development
- Clinical trial participation support
Collaborative Research Ecosystem
Company maintains strategic research partnerships.
| Partnership Type | Number of Collaborations |
|---|---|
| Academic Institutions | 9 active partnerships |
| Pharmaceutical Companies | 4 strategic alliances |
Ethical and Transparent Operations
4D Molecular Therapeutics maintains rigorous compliance standards.
- FDA compliance protocols
- Comprehensive clinical trial transparency
- Robust data integrity practices
Continuous Learning and Development
Investment in employee professional growth.
| Professional Development Metric | 2024 Value |
|---|---|
| Annual Training Hours per Employee | 42 hours |
| Professional Conference Attendance | 17 international conferences |
4D Molecular Therapeutics, Inc. (FDMT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.